Hereditary Risk Evaluation for Borderline Ovarian Tumors Based on Immunohistochemistry
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Borderline ovarian tumors (BOT) are premalignant lesions. Approximately 10% of all epithelial ovarian cancers are known to be hereditary with hereditary breast and ovarian cancer (HBOC) accounting for approximately 90% of cases; the remaining 10% are attributable to Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC). The aim of our study is to estimate this risk based on screening immunohistochemistry (IHC). Methods: Thirty-four patients diagnosed with BOT were identified. Family history, clinical characteristics, and IHC data (breast cancer 1, early onset [BRCA1], breast cancer 2, early onset [BRCA2], mutS homolog 2 [MSH2], mutL homolog 1 [MLH1]) were collected for all cases from the patients’ medical charts. Nuclear staining of the tumor was scored as negative and positive. Results: Among 32 patients, 14 (44%) had serous type and 18 (56%) had mucinous type. The mean patient age was 44 years (range 19-86).The number of patients with weak IHC staining for MSH2 and BRCA2 was 1 (3%) and 6 (19%) respectively. The median follow up was 21.8 months. Conclusion: According to the results, we discovered that 3% and 19% of patients with BOT had a risk of hereditary cancer based on IHC analysis respectively. This pilot study may help clinician to counsel effectively for confirmative tests. (J Menopausal Med 2014;20:14-20)
Abstract
Borderline ovarian tumors (BOT) are premalignant lesions. Approximately 10% of all epithelial ovarian cancers are known to be hereditary with hereditary breast and ovarian cancer (HBOC) accounting for approximately 90% of cases; the remaining 10% are attributable to Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC). The aim of our study is to estimate this risk based on screening immunohistochemistry (IHC). Methods: Thirty-four patients diagnosed with BOT were identified. Family history, clinical characteristics, and IHC data (breast cancer 1, early onset [BRCA1], breast cancer 2, early onset [BRCA2], mutS homolog 2 [MSH2], mutL homolog 1 [MLH1]) were collected for all cases from the patients’ medical charts. Nuclear staining of the tumor was scored as negative and positive. Results: Among 32 patients, 14 (44%) had serous type and 18 (56%) had mucinous type. The mean patient age was 44 years (range 19-86).The number of patients with weak IHC staining for MSH2 and BRCA2 was 1 (3%) and 6 (19%) respectively. The median follow up was 21.8 months. Conclusion: According to the results, we discovered that 3% and 19% of patients with BOT had a risk of hereditary cancer based on IHC analysis respectively. This pilot study may help clinician to counsel effectively for confirmative tests. (J Menopausal Med 2014;20:14-20)
참고문헌 (31)
- Jemal A, "Global cancer statistics", Clin, 61, pp.69~90 (2011)
- Swanton A, "Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review", Obstet Gynecol Reprod Biol, 135, pp.3~7 (2007)
- Gershenson DM, "Clinical management potential tumours of low malignancy", Best Pract Res Clin Obstet Gynaecol, 16, pp.513~527 (2002)
- Lalwani N, "Current update on borderline ovarian neoplasms", Roentgenol, 194, pp.330~336 (2010)
- Silva EG, "The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent", Surg Pathol, 30, pp.1367~1371 (2006)
- Risch HA, "Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649women with ovarian cancer", Hum Genet, 68, pp.700~710 (2001)
- Narod SA, "Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2mutations for ovarian cancer", Curr Opin Obstet Gynecol, 14, pp.19~26 (2002)
- Whittemore AS, "Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer", Hum Genet, 60, pp.496~504 (1997)
- Miki Y, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, 266, pp.66~71 (1994)
- Wooster R, "Identification of the breast cancer susceptibility gene BRCA2", Nature, 378, pp.789~792 (1995)
- Aarnio M, "Cancer risk in mutation carriers of DNA-mismatch-repair genes", Cancer, 81, pp.214~218 (1999)
- Heo EJ, "A case of perimenopausal endometrial cancer in a woman with MSH2germline mutation", Menopausal Med, 19, pp.143~146 (2013)
- Burgart LJ, "Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide", Arch Pathol Lab Med, 129, pp.1385~1389 (2005)
- Boyd J, "Whole exome sequence analysis of serous borderline tumors of the ovary", Gynecol Oncol, 130, pp.560~564 (2013)
- Varga J, "Borderline ovarian tumor - a case report with genetic testing", Gynaecol Oncol, 34, pp.189~192 (2013)
- Kyu-Won Jung, "Prediction of Cancer Incidence and Mortality in Korea, 2012", Cancer Research and Treatment, 44(1), pp.15~31 (2012), 대한암학회
- Dehari R, "The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis", Surg Pathol, 31, pp.1007~1012 (2007)
- McCluggage WG, "The pathology of and controversial aspects of ovarian borderline tumours", Curr Opin Oncol, 22, pp.462~472 (2010)
- Webb PM, "Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer", Gynecol Oncol, 92, pp.232~239 (2004)
- Shin JY, "Costs during the first five years following cancer diagnosis in Korea", Asian Pac J Cancer Prev, 13, pp.3767~3772 (2012)
- Seidman JD, "Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators", Hum Pathol, 31, pp.539~557 (2000)
- Zanetta G, "Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors", Gynecol Oncol, 81, pp.63~66 (2001)
- Prat J, "Hereditary ovarian cancer", Hum Pathol, 36, pp.861~870 (2005)
- Stratton JF, "Contribution of BRCA1 mutations to ovarian cancer", Med, 336, pp.1125~1130 (1997)
- Watson P, "The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer", Gynecol Oncol, 82, pp.223~228 (2001)
- Garg K, "BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas", Surg Pathol, 37, pp.138~146 (2013)
- 김민규, "Synchronous gynecologic malignancy and preliminary results of Lynch syndrome", Journal of Gynecologic Oncology, 22(4), pp.233~238 (2011), 대한부인종양학회
- Cohen SA, "Current Lynch syndrome tumor screening practices: a survey of genetic counselors", Genet Couns, 23, pp.38~47 (2014)
- Jones S, "Low-grade serous carcinomas of the ovary contain very few point mutations", Pathol, 226, pp.413~420 (2012)
- Lee WS, "Expression of p53, p27 and Jab1 protein in epithelial ovarian tumors", Gynaecol Oncol, 33, pp.358~362 (2012)
- 문명진, "에스트로겐 수용체 유전자의 다형성과 자궁내막증", 대한폐경학회지, 19(2), pp.64~73 (2013), 대한폐경학회